, Volume 40, Issue 2, pp 173–179 | Cite as

Viral kinetics during the first weeks of pegylated interferon and ribavirin treatment can identify patients at risk of relapse after its discontinuation: new strategies for such patients?

  • M. Milan
  • S. Boninsegna
  • L. Scribano
  • S. Lobello
  • S. Fagiuoli
  • P. FabrisEmail author
  • A. Buda
  • D. Martines
Clinical and Epidemiological Study



Pegylated interferon (PEG-IFN) and ribavirin is the most effective treatment for chronic hepatitis C virus (HCV) hepatitis, but the rate of sustained virological response (SVR) remains approximately 50%, and 15–20% of all treated patients have a virological relapse after completing the treatment. Studies on the SVR have failed to discriminate between non-responders and relapsers.


To identify the risk factors for relapse among patients with an end-of-treatment response (ETR).


We retrospectively analyzed 281 patients consecutively treated with PEG-IFN and ribavirin with a follow-up period of at least 24 weeks. The baseline details collected on each patient included demographic data, histological features, and biochemical profiles.


Forty-six patients (16.4%) relapsed during the first 6 months of follow-up after discontinuing the therapy. Relapser patients were significantly older, had more steatosis, fibrosis, and showed significantly lower rapid virological response (RVR) rates compared with SVR patients. By logistic regression analysis, only the absence of RVR was found to be significantly associated with relapses in both subgroups of patients with genotypes 1 and 4 (p < 0.004) and those with genotypes 2 and 3 (p < 0.006). Severe fibrosis was also predictive of relapsing disease, but only for genotypes 2 and 3 patients (p < 0.003). During the treatment, serum HCV-RNA decreased more rapidly in patients with SVR compared to non-responder and relapser patients (p < 0.001). Interestingly, relapser patients exhibited an intermediate serum HCV-RNA decay during the first 4 weeks of therapy.


Among HCV patients treated with PEG-IFN and ribavirin, the absence of RVR was the most important independent predictor of relapse, independent of the HCV genotype. In the subgroup of genotypes 2 and 3 patients, the severity of fibrosis was also an important factor associated with the relapse rate.


Predictors HCV Relapse Viral kinetics 


Conflict of interest



  1. 1.
    Shepard CW, Finelli L, Alter MJ. Global epidemiology of hepatitis C virus infection. Lancet Infect Dis. 2005;5:558–67.PubMedCrossRefGoogle Scholar
  2. 2.
    Fried MW, Shiffman ML, Reddy KR, et al. Peginterferon α-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med. 2002;347:975–82.PubMedCrossRefGoogle Scholar
  3. 3.
    Manns MP, McHutchison JG, Gordon SC, et al. Peginterferon α-2b plus ribavirin compared with interferon α-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet. 2001;358:958–65.PubMedCrossRefGoogle Scholar
  4. 4.
    Zeuzem S, Hultcrantz R, Bourlìere M, et al. Peginterferon α-2b plus ribavirin for treatment of chronic hepatitis C in previously untreated patients infected with HCV genotypes 2 and 3. J Hepatol. 2004;40:993–9.PubMedCrossRefGoogle Scholar
  5. 5.
    Shiffman ML, Suter F, Bacon BR, et al. Peginterferon α-2a and ribavirin for 16 or 24 weeks in HCV genotype 2 or 3. N Engl J Med. 2007;357:124–34.PubMedCrossRefGoogle Scholar
  6. 6.
    Mangia A, Santoro R, Minerva N, et al. Peginterferon α-2b and ribavirin for 12 vs. 24 weeks in HCV genotype 2 or 3. N Engl J Med. 2005;352:2609–17.PubMedCrossRefGoogle Scholar
  7. 7.
    Mangia A, Minerva N, Bacca D, et al. Determinants of relapse after a short (12 weeks) course of antiviral therapy and re-treatment efficacy of a prolonged course in patients with chronic hepatitis C virus genotype 2 or 3 infection. Hepatology. 2009;49:358–63.PubMedCrossRefGoogle Scholar
  8. 8.
    von Wagner M, Huber M, Berg T, et al. Peginterferon-α-2a (40KD) and ribavirin for 16 or 24 weeks in patients with genotype 2 or 3 chronic hepatitis C. Gastroenterology. 2005;129:522–7.CrossRefGoogle Scholar
  9. 9.
    Aghemo A, Rumi MG, Soffredini R, et al. Impaired response to interferon-α2b plus ribavirin in cirrhotic patients with genotype 3a hepatitis C virus infection. Antivir Ther. 2006;11:797–802.PubMedGoogle Scholar
  10. 10.
    Fried MW, Jensen DM, Rodriguez-Torres M, et al. Improved outcomes in patients with hepatitis C with difficult-to-treat characteristics: randomized study of higher doses of peginterferon α-2a and ribavirin. Hepatology. 2008;48:1033–43.PubMedCrossRefGoogle Scholar
  11. 11.
    Sánchez-Tapias JM, Diago M, Escartín P, et al. Peginterferon-α2a plus ribavirin for 48 versus 72 weeks in patients with detectable hepatitis C virus RNA at week 4 of treatment. Gastroenterology. 2006;131:451–60.PubMedCrossRefGoogle Scholar
  12. 12.
    Ferenci P, Fried MW, Shiffman ML, et al. Predicting sustained virological responses in chronic hepatitis C patients treated with peginterferon α-2a (40 KD)/ribavirin. J Hepatol. 2005;43:425–33.PubMedCrossRefGoogle Scholar
  13. 13.
    Hadziyannis SJ, Sette H Jr, Morgan TR, et al. Peginterferon-α2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med. 2004;140:346–55.PubMedGoogle Scholar
  14. 14.
    Herrmann E, Lee JH, Marinos G, et al. Effect of ribavirin on hepatitis C viral kinetics in patients treated with pegylated interferon. Hepatology. 2003;37:1351–8.PubMedCrossRefGoogle Scholar
  15. 15.
    Dixit NM, Layden-Almer JE, Layden TJ, et al. Modelling how ribavirin improves interferon response rates in hepatitis C virus infection. Nature. 2004;432:922–4.PubMedCrossRefGoogle Scholar
  16. 16.
    Hofmann WP, Herrmann E, Sarrazin C, et al. Ribavirin mode of action in chronic hepatitis C: from clinical use back to molecular mechanisms. Liver Int. 2008;28:1332–43.PubMedCrossRefGoogle Scholar
  17. 17.
    Rodríguez-Iñigo E, López-Alcorocho JM, Bartolomé J, et al. Percentage of hepatitis C virus-infected hepatocytes is a better predictor of response than serum viremia levels. J Mol Diagn. 2005;7:535–43.PubMedCrossRefGoogle Scholar
  18. 18.
    Dahari H, Layden-Almer JE, Kallwitz E, et al. A mathematical model of hepatitis C virus dynamics in patients with high baseline viral loads or advanced liver disease. Gastroenterology. 2009;136:1402–9.PubMedCrossRefGoogle Scholar
  19. 19.
    Davis GL, Wong JB, McHutchison JG, et al. Early virologic response to treatment with peginterferon α-2b plus ribavirin in patients with chronic hepatitis C. Hepatology. 2003;38:645–52.PubMedCrossRefGoogle Scholar
  20. 20.
    Drusano GL, Preston SL. A 48-week duration of therapy with pegylated interferon α 2b plus ribavirin may be too short to maximize long-term response among patients infected with genotype-1 hepatitis C Virus. J Infect Dis. 2004;189:964–70.PubMedCrossRefGoogle Scholar
  21. 21.
    Berg T, Von Wagner M, Hinrichsen H, et al. Reduction of the relative relapse rate by prolongation of the duration of a therapy with peginterferon α-2a plus ribavirin in patients with genotype 1 infection up to 72 weeks. Hepatology. 2004;40:238A.Google Scholar
  22. 22.
    Kozielewicz D, Dybowska D, Halota W, et al. Natural leukocyte interferon alpha (Alfaferone) combined with ribavirin in the treatment of patients with HCV-related cirrhosis: our experience. Infection. 2011;39:433–7.PubMedCrossRefGoogle Scholar
  23. 23.
    Buti M, Valdés A, Sánchez-Avila F, et al. Extending combination therapy with peginterferon α-2b plus ribavirin for genotype 1 chronic hepatitis C late responders: a report of 9 cases. Hepatology. 2003;37:1226–7.PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag 2011

Authors and Affiliations

  • M. Milan
    • 1
  • S. Boninsegna
    • 1
  • L. Scribano
    • 1
  • S. Lobello
    • 2
  • S. Fagiuoli
    • 3
  • P. Fabris
    • 4
    Email author
  • A. Buda
    • 1
  • D. Martines
    • 1
  1. 1.Department of Surgical and Gastroenterological Sciences, Section of GastroenterologyUniversity of PaduaPaduaItaly
  2. 2.Gastroenterology UnitS. Antonio Hospital, ASL 16PaduaItaly
  3. 3.Gastroenterology UnitBergamo HospitalBergamoItaly
  4. 4.Infectious Diseases and Tropical Medicine UnitSan Bortolo HospitalVicenzaItaly

Personalised recommendations